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AbstrACt
Objectives The aim of this study was to estimate 
the prevalence of chronic fatigue syndrome/myalgic 
encephalomyelitis (CFS/ME) and describe illness 
characteristics in a community population in Poland. 
Design: cross-sectional study.
setting Poland.
Participants Of the cohort of 1400 who self-presented 
with fatigue only 69 subsequently were confirmed as 
having CFS/ME using the Fukuda criteria.
Main outcome measures Participants completed the 
following screening symptom assessment tools: Chalder 
Fatigue Scale, Hospital Anxiety and Depression Scale (HADS), 
Epworth Sleepiness Scale (ESS), Composite Autonomic 
Symptom Score 31 (COMPASS 31), Quality of Life Scale 
(QOLS). Haemodynamic and autonomic parameters were 
automatically measured at rest with a Task Force Monitor.
results In 1308, from 1400 (93%) individuals who 
identified themselves as fatigued, recognised chronic 
conditions were identified, for example, neurological 
(n=280, 21.5%), neurodegenerative (n=200, 15%), 
psychiatric (n=654, 50%) and immunologic (n=174, 
13.5%) disorders. The remaining 69 participants (mean 
age 38.3±8.5) met the Fukuda defintion for CFS/ME 
and had baseline objective assessment. The majority 
had experienced symptoms for over 2 years with 37% 
having symptoms for 2–5 years and 21.7% for more than 
10 years. The COMPASS 31 indicated that 50% have 
symptoms consistent with orthostatic intolerance. About 
43/69 (62%) had Epworth sleepiness scores ≥10, ie, 
consistent with excessive daytime sleepiness, 26/69 
(38%) had significant anxiety and 22/69 (32%) depression 
measured by HADS A & D. Quality of life is significantly 
impaired in those with Fukuda criteria CFS (QLS score 
64±11) with significant negative relationships between 
quality of life and fatigue (p<0.0001), anxiety (p=0.0009), 
depression (p<0.0001) and autonomic symptoms (p=0.04).
Conclusion This is the first study to summarise illness 
characteristics of Polish CFS/ME patients. Our study has 
confirmed that fatigue is a common and under-recognised 
symptom affecting the Polish population.
IntrOduCtIOn
Diagnostics and treatment of the chronic 
fatigue syndrome/myalgic encephalomyelitis 
(CFS/ME) present a challenge to specialists 
as this syndrome is not a clearly identified, 
uniform disease but a set of symptoms resem-
bling those occurring in other diseases, in 
which a sense of chronic fatigue predomi-
nates. In some countries (eg, Poland), CFS/
ME is diagnosed very rarely, which may be 
associated with the fact that the aetiology of 
the disease is still poorly known, and with 
diagnostic problems resulting from a lack 
of detailed and uniform guidelines allowing 
an unambiguous diagnosis and initiation of 
effective treatment in CFS/ME patients.
The available studies provide several diag-
nostic criteria based on a definition of the 
American Centers for Disease Control (CDC), 
the Oxford Criteria, or the Canadian Guide-
lines. Criteria proposed by CDC (Fukuda et 
al. 1994) are most commonly used as accept-
able diagnostic criteria when recruiting CFS/
ME patients for scientific studies. However, 
they are encumbered by several disadvan-
tages (eg, fatigue experienced for at least 
6 months), which—from the point of view 
of clinical practice—may delay a diagnosis 
in patients who do not meet this criterion 
precisely. The Oxford criteria propose a new 
diagnostic approach, focusing mainly on an 
strengths and limitations of this study
 ► This is the first study to summarise illness character-
istics of a cohort of Polish chronic fatigue syndrome/
myalgic encephalomyelitis (CFS/ME) patients.
 ► We used Fukuda criteria to indicate patients with 
CFS/ME.
 ► Recruitment was based on self-identification in re-
sponse to an advertisement in CFS/ME community 
support networks across Poland.
 ► Methodologically, more robust epidemiological stud-
ies of fatigue and its consequences in the Polish 
population are now needed.
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aspect of mental rather than somatic fatigue. The Cana-
dian criteria (CDC) expand the CFS/ME definition with 
additional diagnostic criteria, ie, postexertional malaise 
and presence of neurological, endocrine, cognitive and 
autonomic (orthostatic intolerance) disorders. The 
proposed CFS/ME definition, including malaise and 
symptoms exacerbation after exercise, allows differen-
tiating CFS/ME patients from patients with depression 
or fibromyalgia. Alternative criteria, such as the Inter-
national Consensus Criteria, disclose a further range of 
symptoms pertaining to the neurological, immunolog-
ical, gastrointestinal and autonomic systems.
Its global prevalence, ranging between 0.4% and 2.5%, 
is growing; most commonly, it is observed in the group of 
20–40 year olds, more frequently in professionally active 
women. CFS/ME is considered to be a common condition 
in countries such as the UK, Australia and the USA.1 2 In 
the UK, it affects up to 250 000 individuals with frequen-
cies reported of up to 0.2%.3 In the UK, Fukuda-defined 
cases have a prevalence of 0.2%. In the USA, the preva-
lence of Fukuda-defined cases has been reported between 
0.2%5% and 0.4%. Finding from the Australian cohort 
showed that from 535 patients diagnosed with CFS/ME 
by a primary care physician, 30.28% met Fukuda criteria. 
To date CFS/ME has neither been reported in Poland, 
nor its prevalence defined. There are currently no CFS/
ME clinical services.
The aim of this study was to summarise sociodemo-
graphic and illness characteristics in those reporting 
CFS/ME symptoms in a Polish population. We set out 
to define the presence and characteristics of CFS/ME in 
Poland in order to identify a cohort of those patients who 
could potentially participate in further research studies.
MethOds
setting
This study took place from March 2014 till July 2016.
Participants
Recruitment was based on self-identification in response 
to an advertisement in CFS/ME community support 
networks across Poland, as well as a general advertisement 
on local radio and social media.
Initially any individuals willing to participate were 
directed to a phone line. Within days of setting up the 
phone line, it became clear that this mechanism to iden-
tify and recruit potential participants would be over-
whelmed. The team therefore directed all potential 
participants to a website where more information about 
the study was available and where individuals were invited 
to self-complete the Fukuda criteria online. If individuals, 
on completing the online scoring, felt that they met the 
Fukuda criteria4 within 7 days they were invited to attend 
the research facility. To be eligible for this study, partici-
pants were required to (1) meet Fukuda criteria, (2) be 
between 25 and 65 years of age and (3) be a resident of 
Poland. The identification process is shown in figure 1.
Patient and public involvement
Patients were not involved in the design of this study. 
Results from the current study will be disseminated to 
participants through newsletters in layman terms. We will 
also communicate our results through a number of other 
scientific and non-scientific channels including presenta-
tions at relevant congresses or in relevant fora.
Clinical assessment
Those who fulfilled the eligibility criteria for Centers for 
Disease Control and Prevention (Fukuda) were invited 
to attend the research unit at the chronobiology labora-
tory (windowless and sound-insulated room, temperature 
22°C, humidity 60%). They were seen by members of 
the research team in an assessment that took place over 
40 min. Individuals participated in a standardised base-
line assessment which comprised a battery of symptom 
assessment tools. Those screened as fulfilling criteria for 
CFS/ME4 were also reviewed clinically by a member of the 
research team in order to determine whether their symp-
toms were consistent with these criteria, that there were 
no psychiatric exclusions or other diagnoses that could 
be associated with CFS/ME or where fatigue was not the 
primary complaint. Sixty-nine individuals subsequently 
went on to have a further baseline objective assessment.
symptom assessment tools
Participants completed the following screening symptom 
assessment tools: Chalder Fatigue Scale,5–7 Hospital 
Anxiety and Depression Scale (HADS),8 Epworth Sleep-
iness Scale (ESS),9 Composite Autonomic Symptom 
Score 31 (COMPASS 31) and 10 11 Quality of Life Scale 
(QOLS).10–14
Figure 1 Study protocol.
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Functional assessment of the cardiac and autonomic nervous 
system
Cardiovascular and autonomic nervous system measure-
ments were performed with a dedicated high-tech device—
Task Force Monitor (TFM, CNSystems, Medizintechnik, 
Graz, Austria). The main area of TFM application is beat-
to-beat analysis of heart rate (ECG) oscillometric and 
non-invasive continuous blood pressure measurements 
(oscBP, contBP) and impendance cardiography.15–22 A 
detailed of study protocol and its methodology have been 
presented in our previous articles.23 24
In all cases TFM measurements were performed during 
10 min of supine rest (phase I) and subsequently asked to 
standing (phase II) during which changes in heart rate 
were assessed and where haemodynamic changes were 
consistent with recognised consensus criteria for a diag-
nosis of postural tachycardia syndrome (PoTS) made.25
We classified each individual’s autonomic function 
profile into sympathetic or parasympathetic dominant 
according to their sympathetico-vagal balance during 
10 min of supine rest. This was based on previous studies 
and assessed using the LF/HF ratio which was consid-
ered to suggest a sympathetic dominant pattern if LF/HF 
was >1 and parasympathetic if the ratio was <1.26 27
statistical analyses
Statistical characteristics of measured values were 
presented as arithmetic means and ±SD. The normality 
of continuous variables distribution was evaluated with 
the Shapiro–Wilk test depending on distribution charac-
teristics of analysed variables, the independent samples 
Student's t-test or the Mann–Whitney U test was used to 
evaluate significance of differences between measured 
values obtained in the group of each phenotypes. All 
calculations were performed with the package Statistica 
V.13.0 (StatSoft), with the assumed level of statistical 
significance of α<0.05.
results
recruitment of the cohort—the prevalence of fatigue in a 
Polish population
During the media campaign, 1400 individuals identified 
themselves to the research team as fitting, they believed, 
the criteria for CFS/ME. One thousand and three 
hundred eight of those subsequently were found not to 
meet the Fukuda criteria for CFS/ME.
In the 1308 (93%) individuals who identified them-
selves as fatigued, recognised chronic conditions were 
identified. These were conditions associated with the 
symptom of fatigue and therefore could have been the 
attributable cause for their fatigue symptoms (and there-
fore not consistent with the Fukuda diagnostic criteria). 
These fatigue associated conditions were broadly classified 
into conditions that were: neurological (n=280, 21.5%), 
neurodegenerative (n=200, 15%), psychiatric (n=654, 
50%) and immunologic (n=174, 13.5%) disorders.
Characteristics of a polish cohort of CFs/Me patients meeting 
the Fukuda criteria
Of the total group with CFS/ME, 41 were female (59.4%). 
The majority of individuals had a normal BMI (58%) with 
24 (35%) being considered overweight and 3 (4.3%) 
being obese. Two individuals (2.9%) were considered 
underweight. The majority of individuals were consid-
ered to be of a specialist professional group (engineers).
symptom burden of a polish cohort of CFs/Me patients 
meeting the Fukuda criteria
The majority of those with CFS/ME had had symptoms 
for over 2 years with 37% having symptoms for 2–5 years 
and 21.7% having symptoms for more than 10 years. The 
vast majority described unrefreshing sleep with impaired 
short-term memory and concentration (91.3%), postex-
ertional malaise 89%, multi-joint pain without swelling 
or redness 72.5%, headaches 62.3%, muscle pain 66.7%, 
sore throat 39.1% and tender cervical or axillary lymph 
nodes 30.4%.
Table 1 shows the prevalence of other symptoms iden-
tified in those found to have Fukuda CFS/ME. This illus-
trates the fact that many clinical specialists may come into 
contact with individuals who may subsequently be identi-
fied as having CFS/ME. When COMPASS 31 scores were 
considered these are shown in table 2 with 50% of indi-
viduals with CFS/ME having symptoms consistent with 
orthostatic intolerance. HAD scores were high for both 
Table 1 Other symptoms reported at initial assessment, N 
=69
Specific symptom No %
IBS 12 17.7
Migraine 17 24.6
Seasonal allergy 8 11.6
Slight food intolerance/nausea/alcohol intolerance 40 58.1
Back pain 13 18.8
Tinnitus 9 13.0
Palpitations with no cardiac history 9 13.0
Periodical fever 8 11.6
Sensory disturbances 0 0
Chest symptoms with no medical history 15 21.7
Mood fluctuations 30 43.5
Chronic stress 41 59.4
Overworked/work stress 34 49.3
Shift work 0 0
Care work 3 4.3
Newborn care 7 10.1
Frequent infections 9 13.0
Night hyperhidrosis 22 31.9
Sleep disturbance/hypersomnia 28 40.6
Unexplained anxiety 3 4.3
Sensory disturbance 10 14.5
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anxiety and depression and 43/69 (62%) were found to 
have ESS scores ≥10, ie, consistent with excessive daytime 
sleepiness. Considering scores from HADS A & D, 26/69 
(38%) had scores consistent with significant anxiety and 
22/69 (32%) depression.
Quality of life of a polish cohort of CFs/Me patients meeting 
the Fukuda criteria
Quality of life scores assessed using the QOLS were mean 
(SD) 64 (11). This confirmed that quality of life is signifi-
cantly impaired in those with Fukuda criteria CFS/ME 
and well below the expected for a healthy population. 
When we considered the relationship between quality 
of life and the other symptoms frequently seen in those 
with CFS/ME, there were strong significant negative rela-
tionships between quality of life and fatigue (p<0.0001), 
anxiety (p=0.0009), depression (p<0.0001) and auto-
nomic symptoms (p=0.04), figure 2. There were no signif-
icant relationships between age or daytime sleepiness.
Autonomic function in a polish cohort of CFs/Me patients 
meeting the Fukuda criteria
When we classified the cohort according to predom-
inance of sympathetic or parasympathetic function, 
44/69 (64%) were found to be sympathetic predominant 
and 25 parasympathetic. When we considered symptom 
burden between these two phenotypes, there were no 
significant differences in symptoms or impact on quality 
of life between the groups (table 3). At rest, the sympa-
thetic predominant group had significantly higher heart 
rate, ER and LF HRV and reduced LVET, PEP and HF 
HRV compared with the parasympathetic group. The 
total PSD was comparable between groups however 
sympatheticovagal balance was different between the 
Table 2 Composite Autonomic Symptom Score 31—
Autonomic symptoms, N =69
Specific symptom No %
Orthostatic intolerance 40 50.0
Dizziness/headaches 41 59.4
Sudden paleness 25 36.2
Arrhythmia 29 42.0
Dryness eyes mouth 45 65.2
Vasomotor 24 34.8
Secretomotor 30 43.5
Upper gastrotract symptoms 38 55.1
Unknown gastropain 26 37.7
Constipation 21 30.4
Diarrhoea 28 40.6
Urinary 21 30.4
Sexual failure 19 27.5
Sleep 68 98.5
Pupilomotor 28 40.6
Anxiety 34 49.3
Figure 2 The relationship between quality of life measured 
using the QOLS scale and (A) fatigue severity assessed 
using the fatigue impact scale (B) anxiety measured using 
the HADS Anxiety Scale (HADS-1) (C) depression measured 
using the HADS Depression Scale (HADS-2) and D) 
autonomic symptom burden measured using the COMPASS 
31.
Table 3 Baseline quality of life scores, N =69
Variable
Total group
Sympathetic dominant 
(n=44)
Parasympathetic 
dominant (n=25)
P valueMean SD Mean SD Mean SD
Chalder Fatigue Scale 25.3 3.7 25.5 3.8 25.0 3.8 >0.05
Fatigue Severity Scale 48.8 8.7 48.0 8.5 50.2 9.1 >0.05
Fatigue Impact Scale 92.2 26.2 92.6 24.6 91.6 29.2 >0.05
HADS_A 9.6 3.4 9.3 3.1 10.1 3.9 >0.05
HADS_D 8.5 3.1 8.5 3.0 8.6 3.4 >0.05
BDI 17.6 8.1 18.3 8.3 16.4 7.9 >0.05
Epworth Sleepiness Scale 10.3 5.6 10.6 5.3 9.8 6.2 >0.05
Quality of Life Scale 63.5 10.9 62.1 11.9 65.9 8.8 >0.05
Orthostatic Grading Scale 8.4 3.1 3.5 3.4 3.4 2.5 >0.05
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phenotypes with increased LF BPV in both diastolic 
and systolic blood pressure, reduced baroreflex sensi-
tivity in those with the sympathetic dominant phenotype 
(table 4).
Those with the parasympathetic predominant pheno-
type were more likely to have had the disease for between 
5 and 10 years (table 5).
Prevalence of postural tachycardia syndrome in a Polish 
cohort of CFs/Me patients
The presence of PoTS  is frequently seen in those with CFS.28 29 
A total of 35 (51%) of the CFS group had haemodynamic 
responses to standing consistent with a diagnosis of PoTS. 
There was no difference in the proportion of those with PoTS 
in the sympathetic or parasympathetic groups (table 5).
Table 4 Cardiovascular/autonomic parameters
Variable
Total group (n=69)
Sympathetic dominant 
(n=44)
Parasympathetic 
dominant (n=25)
P valueMean SD Mean SD Mean SD
Haemodynamics HR 67.6 9.2 70.1 8.4 63.2 9.0 0.0017
Sbp 117.3 13.3 118.5 11.3 115.2 16.2 >0.05
Dbp 79.3 10.6 79.6 9.7 78.8 12.1 >0.05
mBP 95.9 11.1 96.0 9.9 95.7 13.2 >0.05
Cardiac 
impedance
SI 52.3 12.4 50.8 12.5 54.9 12.1 >0.05
CI 3.5 0.8 3.5 0.8 3.4 0.8 >0.05
TPRI 2304.7 747.3 2285.2 684.3 2339.0 861.1 >0.05
EDI 85.0 19.9 82.3 19.9 89.7 19.5 >0.05
IC 62.8 21.2 59.7 20.6 68.2 21.5 >0.05
ACI 85.7 34.4 80.4 33.8 95.0 34.3 >0.05
LVWI 4.4 1.1 4.5 1.1 4.4 1.2 >0.05
LVET 318.2 17.3 313.2 18.2 327.0 11.1 0.0005
TFC 31.3 4.5 30.8 4.7 32.3 4.0 >0.05
PEP 110.2 12.1 107.1 11.3 115.7 11.6 0.0040
STR 34.9 4.3 34.6 4.7 35.5 3.4 >0.05
ER 35.5 3.3 36.3 2.6 34.2 3.9 0.0092
MSER 300.8 68.9 306.2 72.5 291.4 62.4 >0.05
REP 77.8 16.8 79.7 19.8 74.5 9.1 >0.05
HI 0.3 0.1 0.3 0.1 0.4 0.1 >0.05
RZ 187.1 12.2 185.3 11.1 190.4 13.6 >0.05
TAC 2.6 0.7 2.5 0.7 2.8 0.8 >0.05
Heart rate 
variability
LFnu-RRI 54.2 17.2 62.2 14.0 40.1 12.7 0.0000
HFnu-RRI 45.8 17.2 37.8 14.0 59.9 12.7 0.0000
PSD-RRI 1684.1 1993.7 1604.9 2166.9 1823.4 1678.7 >0.05
LF/HF-RRI 1.7 1.6 2.3 1.8 0.8 0.4 0.0000
Diastolic blood 
pressure 
variability
LFnu-Dbp 52.2 14.7 59.7 10.2 38.9 11.7 0.0000
HFnu-dBP 14.0 10.4 11.0 7.5 19.3 12.7 0.0004
PSD-dBP 13.6 16.5 15.2 19.3 10.8 9.5 >0.05
LF/HF-dBP 6.6 6.2 8.7 6.8 2.8 1.8 0.0000
Systolic blood 
pressure 
variability
LFnu-sBP 42.1 13.5 47.5 10.7 32.6 12.9 0.0000
HFnu-sBP 16.5 10.8 15.6 11.0 18.2 10.4 >0.05
PSD-sBP 20.2 30.2 17.5 16.3 25.0 45.5 >0.05
LF/HF-sBP 3.8 2.8 4.5 3.0 2.5 1.7 0.0019
Baroreflex 
parameters
Total event count 17.4 13.6 21.5 14.4 10.2 8.4 0.0006
Total slope mean 19.6 13.0 16.7 8.9 24.8 17.2 0.0114
Total BEI 70.5 15.1 72.4 14.2 67.0 16.4 >0.05
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dIsCussIOn
This study has confirmed for the first time that chronic 
fatigue is a common symptom experienced by the Polish 
population and that CFS/ME is an under-recognised 
syndrome in this group. The key finding of this study is 
that prevalence is similar to reported data in the other 
countries and is associated with a large symptom burden 
and impaired quality of life.
Of the cohort of 1400 who self-presented with fatigue 
only 69 subsequently were confirmed as having CFS/ME 
using the Fukuda criteria. This suggests that in Poland 
there are significant amounts of fatigue related to other 
conditions, with only a small percentage of those expe-
riencing fatigue having CFS/ME per se (69/1400; 5%).
From the initial responses, we rigorously identified 
those who met with Fukuda criteria for CFS/ME. We 
did this by asking individuals to complete the tool, but 
also using face to face sessions with trained clinicians. 
We believe therefore, that our cohort represents a well 
characterised group who we are confident fulfil one of 
the recognised diagnostic criteria for CFS/ME. When 
we compared this Polish cohort with CFS/ME to other 
national cohorts there were some similarities, but also 
some differences.
Compared with the UK cohort30 having in excess of 
6500 individuals collected from the UK NHS Clinical CFS 
services, the Polish cohort appeared to be of a similar age 
to the UK cohort with comparable levels of fatigue and 
illness duration, have similar levels of sleep and cognitive 
symptoms but less postexertional malaise, muscle pain 
and headaches. The Polish cohort appeared to have more 
males than was seen in the UK cohort.
As in previous national cohorts,3 30 31 the presence of 
fatigue in the Polish population was associated with 
impaired quality of life. As has been seen previously, 
impaired quality of life associates with the severity of 
symptoms such as fatigue and autonomic dysfunction, 
but in contrast to other studies, not daytime sleepiness. 
Impaired quality of life is also associated with increased 
anxiety and more depression. As in other series, we would 
suggest that this association is a secondary phenomenon 
that is, arising as a consequence of the condition rather 
than a cause. The fact that we rigorously excluded depres-
sion and psychiatric disorders when determining the 
criteria would be consistent with this.
Our study has also confirmed a high prevalence of the 
condition PoTS. This form of dysautonomia21 has been 
recognised as occurring frequently in those with CFS/
ME,28 29 and represents a potential therapeutic target in 
those with this illness. It is important that clinicians and 
researchers are aware of the overlap and are trained to 
identify and manage this condition.
All of these differences might arise because of the 
self-report nature of the Polish cohort and that the UK 
cohort was recruited from the National Health Service 
clinical services which were specifically set up to iden-
tify and manage CFS/ME.3 A comprehensive review of 
the prevalence of CFS/ME in three regions of England 
involving 143 000 subjects suggested an older cohort with 
longer disease duration than that seen in the UK clinical 
services.
An Australian cohort31 was established using similar 
identification strategies to our Polish cohort with self-re-
port in response to adverts inviting individuals to partic-
ipate in a research database. Individuals in this cohort 
were included if they had received the diagnosis from a 
primary care physician. Again the proportion of females 
in the Australian cohort was higher than in the Polish 
cohort
This study has a number of limitations. The case ascer-
tainment process used self-report as the means of iden-
tifying those with CFS/ME. It became clear during the 
radio and television campaign that there was consid-
erable interest, and as a result our recruitment process 
needed to be changed to facilitate timely screening of 
those self-presenting with fatigue. It is clear that a thor-
ough, methodologically robust epidemiological study of 
fatigue and its consequences in a Polish population are 
now needed.
Our study has confirmed that fatigue is a common and 
under-recognised symptom affecting the Polish popula-
tion. It impacts on quality of life and is associated with 
Table 5 PoTS (sympathetic, N =44; parasympathetic, N=25)
Sympathetic dominant Parasympathetic dominant 
P valueNo % No %
PoTS 22 45.5 12 48 >0.05
Fatigue period 
6 month–2 years 8 22.9 8 23.5 >0.05
  2–5 years 14 40.0 12 35.3 >0.05
  5–10 years 4 11.4 8 23.5 0.0492
  More than 10 years 9 25.7 6 17.6 >0.05
Fatigue period IQR 2–5 years 6  month–2  years 
Fatigue period in years IQR 8 2.5 
PoTS, postural tachycardia syndrome. 
 o
n
 19 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023955 on 7 March 2019. Downloaded from 
7Słomko J, et al. BMJ Open 2019;9:e023955. doi:10.1136/bmjopen-2018-023955
Open access
a range of other symptoms that have been previously 
recognised in other cohort studies. Despite this, there are 
no clinical services for fatigue or CFS/ME in Poland and 
it is poorly understood and infrequently diagnosed. Our 
research programme now aims to consider the effect of 
interventions on fatigue in a Polish CFS/ME population.
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